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Toward a More Accurate Estimate of the Prevalence
of Hepatitis C in the United States
Brian R. Edlin,1,2 Benjamin J. Eckhardt,1 Marla A. Shu,3 Scott D. Holmberg,4 and Tracy Swan5
Data from the 2003-2010 National Health and Nutrition Examination Survey (NHANES)
indicate that about 3.6 million people in the United States have antibodies to the hepatitis
C virus, of whom 2.7 million are currently infected. NHANES, however, excludes several
high-risk populations from its sampling frame, including people who are incarcerated,
homeless, or hospitalized; nursing home residents; active-duty military personnel; and peo-
ple living on Indian reservations. We undertook a systematic review of peer-reviewed litera-
ture and sought out unpublished presentations and data to estimate the prevalence of
hepatitis C in these excluded populations and in turn improve the estimate of the number
of people with hepatitis C in the United States. The available data do not support a precise
result, but we estimated that 1.0 million (range 0.4 million-1.8 million) persons excluded
from the NHANES sampling frame have hepatitis C virus antibody, including 500,000
incarcerated people, 220,000 homeless people, 120,000 people living on Indian reserva-
tions, and 75,000 people in hospitals. Most are men. An estimated 0.8 million (range 0.3
million-1.5 million) are currently infected. Several additional sources of underestimation,
including nonresponse bias and the underrepresentation of other groups at increased risk
of hepatitis C that are not excluded from the NHANES sampling frame, were not addressed
in this study. Conclusion: The number of US residents who have been infected with hepatitis
C is unknown but is probably at least 4.6 million (range 3.4 million-6.0 million), and of
these, at least 3.5 million (range 2.5 million-4.7 million) are currently infected; additional
sources of potential underestimation suggest that the true prevalence could well be higher.
(HEPATOLOGY 2015;62:1353-1363)
See Editorial on Page 1339
E
stimates of the number of persons with hepatitis
C in the United States are important for assessing
the burden of disease caused by the epidemic,
designing and targeting public health interventions, allo-
cating resources, and planning for future health care
needs. Designed to assess the health and nutritional sta-
tus of adults and children in the United States, the
National Health and Nutrition Examination Survey
(NHANES), a probability sample of the US household
population, provides extensive information on the prev-
alence of major diseases and disease risk factors.1 About
10,000 persons of all ages in about 30 counties are inter-
viewed during each 2-year survey cycle.2 The data are
used to develop public health policy, direct and design
health programs and services, expand the health knowl-
edge for the nation, and monitor progress toward
Healthy People objectives.1 Blood specimens are tested
for hepatitis C virus (HCV) antibody and RNA to esti-
mate the number of persons with hepatitis C in the
United States.3 The most recent results suggest that dur-
ing 2003-2010 about 3.6 million persons (95%
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confidence interval 3.0 million-4.2 million) had anti-
body to HCV, indicating past or present infection, of
whom about 2.7 million (95% confidence interval 2.2
million-3.2 million) had HCV RNA-positive serum,
indicating current infection.3
But while NHANES provides a wealth of valuable data
on the health of the US population,1 it was designed to esti-
mate the prevalence of conditions substantially more com-
mon than hepatitis C.4 For estimating hepatitis C
prevalence, it suffers from three potential sources of underes-
timation. First, its sampling frame is the noninstitutional-
ized, housed, civilian population of the United States. By
design it omits several large populations of persons at
increased risk of HCV infection, including homeless per-
sons, those in jail or prison, and those living on Indian reser-
vations. Second, several additional groups at increased risk
of hepatitis C, while not excluded from the NHANES sam-
pling frame, are poorly represented because of small sample
sizes, including Puerto Rican Americans,5 other ethnic
minorities,6 and people born in high-prevalence countries.7-
9 Third, nonresponse bias4 could result in underestimation
if persons at elevated risk of hepatitis C differentially opt not
to participate or do not provide a blood specimen.
NHANES investigators have emphasized the need to
account for its omission of high-prevalence groups.3,4,10,11
To develop a more accurate estimate of the national burden
of hepatitis C, we examined the first of these three potential
sources of underestimation. We estimated the HCV preva-
lence of six populations excluded from NHANES — peo-
ple who are homeless, incarcerated, or hospitalized; nursing
home residents; active-duty military personnel; and Native
Americans living on reservations. We used these data to
revise the most recent NHANES estimate.
Materials and Methods
Data Sources and Searches. We used publicly
available estimates of the size of each of the six popula-
tion groups excluded from the NHANES sampling
frame (Table 1).12-19 We averaged all available estimates
from the years 2003 through 2010 for each group. Hos-
pitalized patient population estimates were obtained by
multiplying the number of discharges in each available
year by the average length of stay for that year and divid-
ing by the number of days in the year; estimates for non-
federal and Veterans Affairs hospitals were added. All
population size estimates reflected the number of people
in each population at a single point in time, to ensure
that people who move among populations are counted
only once. Many more people are homeless during a
given year than on a single night,13 and hepatitis C esti-
mates that use those numbers20 are therefore severalfold
higher than ours.
We then used OVID to systematically search the
MEDLINE and Embase databases for articles and confer-
ence proceedings reporting the prevalence of HCV anti-
body in each of the six populations, limiting our search
to studies conducted within 10 years of the period of the
NHANES estimate (2003-2010) (Table 2). We also
searched “related articles” listings, examined the referen-
ces of retrieved papers, and contacted authors of pub-
lished data for additional unpublished information.
Study Selection. Studies that reported HCV sero-
prevalence in representative or unselected samples of
one of the excluded population groups in the United
States were included; those which sampled subjects at
selectively higher risk by virtue of risk factors, symp-
toms, or requests for testing were excluded.
Data Extraction and Quality Assessment. One
investigator extracted the data from each study, and at
least one additional investigator verified the accuracy of
the data. The dates of testing, number of persons tested,
number of persons testing HCV antibody-positive, and
HCV seroprevalence were extracted. Authors were con-
tacted to obtain data missing from published reports.
Table 1. Estimated Size of Population Groups Excluded from NHANES
Population Estimated Size Source Years
Incarcerated people 2,186,230 Bureau of Justice Statistics12 2005, 2008, 2009, 2010
Homeless people 691,899 US Department of Housing
and Urban Development13
2005, 2006, 2007, 2008, 2009, 2010
Hospitalized patients 478,054
Nonfederal hospitals CDC/NCHS National Hospital
Discharge Survey14
2005, 2007, 2008, 2009, 2010
Veterans Affairs hospitals Department of Veterans Affairs15 2003, 2004, 2005, 2006, 2007,
2008, 2009, 2010
Nursing home residents 1,446,959 National Nursing Home Survey16 2004
US Census Bureau17 2009
Active-duty military 1,404,060 US Census Bureau18 2005, 2007, 2008, 2009, 2010
Native Americans living on reservations 1,069,411 US Census Bureau19 2010
Abbreviations: CDC/NCHS, Centers for Disease Control and Prevention/National Center for Health Statistics.
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Data Synthesis and Analysis. For the incarcerated
population, available seroprevalence estimates for each
state were averaged and a national estimate was calculated
by weighting the state averages by the size of each state’s
incarcerated population.21 Where separate estimates were
available for men and women, they were weighted accord-
ing to the sex ratio of prisoners for the respective state.22
For each of the other groups, we calculated the mean sero-
prevalence of the available studies, weighting each study
by its sample size. We calculated binomial confidence
intervals for the seroprevalence estimate from each study
where available data permitted. To conservatively account
for interstudy variability within each of the six population
groups, we used the range of the point estimates from the
separate studies to represent the uncertainty in our esti-
mate. The size of each population group was multiplied
by its estimated seroprevalence, and the totals were
summed and added to the 2003-2010 NHANES estimate
for the number of US residents with HCV antibody. To
estimate the number of persons with current HCV infec-
tion, we used the NHANES finding that 82% of
antibody-positive persons have HCV RNA.3 The same
proportion, 82%, was observed in a high-prevalence sam-
ple of people who inject drugs.23 This analysis updates an
earlier one that used the same methods.24
Results
The sizes of the six population groups ranged from
478,054 to 2,186,230 (Table 1). The search for seropre-
valence data yielded 2828 unique articles, of which 36
met criteria for inclusion (Table 2), with seven addi-
tional studies published in abstract form only.20,25-66
One study of prisoners and two studies of hospitalized
patients were excluded because they were conducted
>10 years before 2003.
Sixteen published studies and six studies published in
abstract form only reported HCV seroprevalence among
persons in penal institutions in 23 states (Table 3). The
studies differed in sample design and methodology.
Most, but not all, sampled persons as they entered these
institutions. The weighted mean prevalence of HCV
antibody among all persons in all studies combined was
23.1%. The prevalences in the 22 studies ranged from
7.5% through 44.0%.
Nine studies of HCV seroprevalence among homeless
persons have been published (Table 4). The study design
and selection criteria differed in each study. The weighted
mean prevalence of HCV antibody among all persons in
all studies combined was 32.1%. The prevalences in the
nine studies ranged from 7.5% through 52.5%.
Seven studies of HCV seroprevalence among persons
in hospitals have been published, and an additional
study was published in abstract form only (Table 4).
One studied source patients of needle-stick injuries; two
were conducted in emergency departments and two in a
psychiatric hospital, with HCV antibody prevalences
between 4.0% and 38% in all the studies. The weighted
mean prevalence of HCV antibody among persons in all
these studies combined was 15.6%.
One small study in nursing home residents demon-
strated an HCV seroprevalence of 4.5%. A random
sample of 10,000 active-duty military personnel found
an HCV antibody prevalence of 0.48%, and a smaller
study of military blood donors showed a seroprevalence
of 0.84%. A single study of Native Americans served by
the Indian Health Service reported an HCV seropreva-
lence of 11.5% (Table 4).
When we multiplied the estimated seroprevalence for
each of the six populations by the population size, we
projected that in 2003-2010 505,350 incarcerated peo-
ple, 222,100 homeless individuals, 74,576 hospitalized
patients, 65,113 nursing home residents, 7020 active
military personnel, and 123,224 persons living on
Indian reservations had HCV antibody. Summing these,
we estimated that 997,384 (range 355,466-1,813,661)
persons in the United States had HCV antibody in addi-
tion to the NHANES estimate (Table 5). Of these, an
estimated 817,855 (range 291,482-1,487,202) are cur-
rently infected.
Table 2. Search Terms and Results of Literature Search for Articles with Hepatitis C Prevalence Data in Populations
Excluded From NHANES
Population Search Terms
Medline
Articles
Embase
Articles
Unique
Articles
Full Text
Screened
Articles
Included
Incarcerated “hepatitis C” and “prison” or “jail” or “incarceration” 651 766 879 51 16
Homeless “hepatitis C” and “homeless” 173 223 245 31 9
Hospitalized “hepatitis C” and “hospitalized” or “emergency room” or “emergency ward” or “inpatient” 559 1252 1340 31 7
Nursing homes “hepatitis C” and “nursing home,” “nursing facility,” or “long-term care facility” or “skilled nursing facility” 13 38 38 12 1
Military “hepatitis C” and “military,” “navy,” “air force,” “army,” or “marines” 172 207 228 15 2
Native Americans “hepatitis C” and “Native American,” “Indian, North American” or “Indian reservation” 55 74 98 19 1
Total 1623 2560 2828 159 36
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Adding these numbers to the most recent NHANES
estimate suggests that at least 4.6 million people in the
United States (range 3.4 million-6.0 million) have HCV
antibody (Table 6). Of these, we project that at least 3.5
million (range 2.5 million-4.7 million) are currently
infected (Table 6).
Sex-specific prevalence data allowed us to estimate
the proportions of men and women among the
infected in three of the excluded populations (see
Appendix A). Men predominated in the excluded
populations overall, as well as among the infected per-
sons in those populations. Men comprised 87.8% of
infected prisoners, 74.5% of infected homeless per-
sons, and 90.9% of infected military personnel com-
pared with 64% of infected persons in the NHANES
population.3 Thus, NHANES appears to underesti-
mate the numbers of HCV-infected men more than
women.
Discussion
Estimates of disease prevalence are important for estab-
lishing disease burdens, identifying health disparities, guid-
ing policy, targeting interventions, and allocating resources.
This analysis highlights several challenges to estimating the
national prevalence of hepatitis C. First, while household
surveys contribute invaluable information about popula-
tion health, to be accurate their findings must be adjusted
to account for populations not sampled or not well repre-
sented in the sample. NHANES uses consistent, standar-
dized methodology that allows monitoring of trends over
time but yields prevalence estimates that underrepresent
the total burden of hepatitis C in the United States. Figures
derived from NHANES appear to underestimate the US
HCV seroprevalence by at least 1 million persons. Prob-
ably at least 4.6 million Americans have HCV antibody
and at least 3.5 million are currently infected.
Table 3. Hepatitis C Seroprevalence Studies in Incarcerated Populations*
State Reference Study Dates Total No. Tested
No. HCV
Antibody-Positive
HCV Antibody
Prevalence
95% Confidence
Interval
California Ruiz et al.25 1994 4513 1859 41.2% 39.8%-42.6%
Ruiz et al.26 1999 5595 1850 33.1% 31.8%-34.3%
Hennessey et al.27† 1999-2000 505 10.0% 9.0%-11.0%‡
Fox et al.28 2001 467 160 34.3% 30.0%-38.8%
Colorado Spaulding et al.29 1996 1224 30.0% 27%-33%
Connecticut§ Fennie et al.30 1996k 174 56 32.2% 25.3%-39.7%
Georgia Spaulding et al.31† 2011 4918 371 7.5% 6.8%-8.3%
Illinois Hennessey et al.27† 2000 447 14.0% 13.0%-16.0%‡
Indiana Varan et al.20 2003, 2011 20,506 2198 10.7% 10.3%-11.2%
Iowa Varan et al.20 2001 23.6%
Maryland Solomon et al.32 2002 3661 1089 29.7% 28.3%-31.3%
Massachusetts Cocoros et al.33 2009-2011 596 122 20.5% 17.3%-23.9%
Lincoln et al.34 1999 463 96 20.7% 17.1%-24.7%
Eastman et al.35 2000 816 290 35.5% 32.3%-38.9%
Michigan Hennessey et al.27† 1999 340 15.0% 14.0%-16.0%‡
Varan et al.20 2004, 2009 4709 10.4%
Missouri Wenger et al.36† 2012-2013 304 50 16.4% 12.5%-21.1%
Montana Varan et al.20 2012 13.9%
Nebraska Varan et al.20 2011 4652 448 9.6% 8.8%-10.5%
Nevada Chen et al.37 2001 24.4% 20.5%-28.6%
New Mexico Varan et al.20 2010 3980 1636 41.1% 39.6%-42.7%
Varan et al.20 2011 40.9%
New York Alvarez et al.38 2009-2013 2788 295 10.6% 9.5%-11.8%
Wang et al.39,40 2000-2009 19,939 2620 13.1% 12.7%-13.6%
North Dakota Varan et al.20 2008-2011 11.2%
Oregon Varan et al.20 2000, 2005 26.7%
Pennsylvania Larney et al.41 2004-2012 101,727 18,454 18.1% 17.9%-18.4%
Rhode Island§ Macalino et al.42 1996-1997 297 119 40.1% 34.4%-45.9%
Macalino et al.43 1998-2000 4264 983 23.1% 21.8%-24.3%
Texas Baillargeon et al.44 1998-1999 3712 1076 29.0% 27.5%-30.5%
Washington Varan et al.20 2008-2011 25,167 4736 18.8% 18.3%-19.3%
Wisconsin Pfister et al.45 1999 1233 13.5% 11.3%-15.3%
Weighted prevalence estimate: 23.1% Range: 7.5%-44.0%
*All data from state prison systems unless otherwise indicated.
†Data from local jails.
‡Confidence interval reported by authors.
§Data from combined prison and jail.
kYear of publication.
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Second, household surveys underestimate the preva-
lence of conditions concentrated in disenfranchised pop-
ulations and, therefore, underestimate the extent of
health disparities. The largest contributions to the hepa-
titis C underestimate are from prisoners, homeless per-
sons, and residents of Indian reservations—marginalized
groups facing social stigma, economic disadvantage, ele-
vated rates of comorbidities, severe health disparities,
and reduced access to high-quality health care. These
groups also include a disproportionately high represen-
tation of ethnic minorities affected by health disparities
and ethnic bias. It is particularly important that these
vulnerable populations are not overlooked when allocat-
ing resources, designing interventions, and planning for
health care needs.
Third, this analysis reveals the paucity of reliable data
on the prevalence of hepatitis C in populations known
to be at increased risk of the disease. A number of
Table 4. Hepatitis C Seroprevalence Studies in Homeless, Hospitalized, Nursing Home, Military, and Native American
Populations
Reference Location Study Dates
Total No.
Tested
No. HCV
Antibody-Positive
HCV Antibody
Prevalence
95% Confidence
Interval
Homeless people
Desai et al.46 Bedford, MA 1993-1998 418 184 44% 39.2%-48.9%
Nyamathi et al.47 Los Angeles, CA 1995-1999 884 197 22% 19.6%-25.2%
Cheung et al.48 Palo Alto, CA 1995-2000 787 314 39.9% 36.5%-43.4%
Rosenblum et al.49 New York, NY 1997-1998 139 45 32% 24.7%-40.8%
Schwarz et al.50 Baltimore, MD 2001-2004 168 32 19% 13.4%-25.8%
Stein and Nyamathi51 Los Angeles, CA 2002-2003 198 104 52.5% 45.3%-59.6%
Gelberg et al.52 Los Angeles, CA 2003-2004 534 26.7% 23.1%-30.8%*
Strehlow et al.53 8 cities 2003-2004 387 120 31.0% 26.4%-35.9%
Boyce et al.54 Hawaii 2006 40 3 7.5% 1.6%-20.4%
Weighted mean prevalence: 32.1% Range: 7.5%-52.55
Hospitalized patients
Austin et al.55 Atlanta, GA VA hospital 1993-1994 530 56 10.6% 8.1%-13.5%
Pham et al.56 Washington, DC VA hospital 1994 839 173 20.6% 17.9%, 23.5%
Cheung57 Palo Alto, CA VA hospital 1994-1997 72 13 18% 10.0%-28.9%
Brillman et al.58 Albuquerque, NM Emergency department 1996 223 38 17% 12.3%-22.6%
Meyer59 Salem, OR Psychiatric hospital 1999-2001 507 103 20.3% 16.9%-24.1%
Tabibian et al.60 Los Angeles, CA Psychiatric VA hospital 2002-2003 129 49 38% 29.6%-46.9%
Hall et al.61 Grand Rapids, MI Emergency department 2005 404 16 4.0% 2.3%-6.4%
Calore et al.62 Palo Alto, CA VA hospital 2007-2009 381 32 8.4% 5.8%-11.6%
Weighted mean prevalence: 15.6% Range: 4.0%-38.0%
Nursing home residents
Chien et al.63 St. Louis, MO 1996-1997 199 9 4.5% 2.1%-8.4%
Weighted mean prevalence: 4.5% Range: 2.1%-8.4%
Active-duty military
Hyams et al.64 United States 1997 10,000 48 0.48% 0.35%-0.64%
Hakre et al.65 US Service members in Iraq or Afghanistan 2002-2007 475 4 0.84% 0.23%-2.14%
Weighted mean prevalence: 0.50% Range: 0.48%-0.84%
Native Americans living on reservations
Neumeister et al.66 Omaha, NE 2007† 243 28 11.5% 7.8%-16.2%
Weighted mean prevalence: 11.5% Range: 7.8%-16.2%
*Confidence interval reported by authors.
†Year of publication.
Abbreviation: VA, Veterans Affairs.
Table 5. Estimated Numbers of HCV Infections in Population Groups Excluded From NHANES
HCV Prevalence Number of Infected Persons
Population Estimated Size Estimate Range Estimate Range
Incarcerated 2,186,230 23.1% 7.5%-44.0% 505,350 163,967-961,941
Homeless 691,899 32.1% 7.5%-52.5% 222,100 51,892-363,246
Hospitalized 478,054 15.6% 4.0%-38.0% 74,576 19,122-181,660
Nursing homes 1,446,959 4.5% 2.1%-8.4% 65,113 30,386-121,545
Military 1,404,060 0.5% 0.48%-0.84% 7020 6,739-11,794
Indian reservations 1,069,411 11.5% 7.8%-16.2% 123,224 83,358-173,474
Total 997,384 355,466-1,813,661
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limitations of the available data impair the accuracy of
the estimates presented here. First, there are no represen-
tative samples of five of the six populations examined.
The seroprevalence studies we used, with the exception
of a single study of active-duty military personnel, were
not designed to recruit nationally representative sam-
ples. Second, the size of two of the populations is not
known with accuracy. There is no precise estimate of the
number of homeless persons in the United States,67,68
and the US census faces substantial challenges in enu-
merating the Native American population on reserva-
tions.69,70 Third, HCV seroprevalence studies were
available from jails and prisons in only 23 states and no
federal prisons. While these states cannot be considered
representative of the United States as a whole, it is worth
noting that taken together they account for 55% of the
nation’s prisoners. Fourth, HCV seroprevalence esti-
mates were available for only nine homeless samples and
eight hospitals, including several Veterans Affairs and
psychiatric hospitals, which may have higher rates of
HCV seroprevalence than other hospitals. Fifth, only a
single clinic-based study of Native Americans was avail-
able, which might have overestimated the hepatitis C
prevalence in that population. Surveillance data suggest,
however, that the prevalence of hepatitis C on Indian
reservations is elevated.71,72 It should also be noted that
we did not examine the ethnic composition of the
undercounted persons we report and that our methods
cannot be used to monitor trends over time. Finally,
studies showing higher prevalence rates may have been
more likely to be published, which would have biased
our estimates upward.
But balanced against these possible sources of overes-
timation are several reasons the current study may still
underestimate the number of infected persons. First,
persons in temporary or unstable housing outnumber
those who are literally homeless on any given night by
severalfold.67,68,73 For example, an estimated 6.8 mil-
lion people were “doubled-up”—i.e., living with
others—in 2010.74 Persons not in their “usual place of
residence” were not included in NHANES. While the
HCV seroprevalence of this precariously housed popula-
tion is not known, these persons could conservatively
account for another half-million to 1 million or more
additional persons with HCV antibody.
Second, nearly all of the prison studies cited in our
study sampled new entrants to prison, who are on aver-
age younger than the overall prison population and
include fewer members of the higher-prevalence birth
cohorts. HCV seroprevalence in the United States
peaked among persons born during 1945-1965.10,75
Adjusting seroprevalence of prisoners for this difference,
an average of about 3 years, would add 2.45% to the
seroprevalence estimate, or about 50,000 additional
infected persons (see Appendix B).
Third, nearly one-third of persons sampled by
NHANES were not interviewed or did not provide a
blood specimen. The NHANES HCV seroprevalence
estimate is based on only 381 positive antibody tests,
while 13,824 sampled persons were not interviewed or
did not provide a blood sample.3 If even 1%-2% of
these unsampled persons had injected illicit drugs
unsafely and did not want to be asked questions about
their health behavior, reveal needle tracks, undergo what
may have been a painful or embarrassing phlebotomy
experience, or participate in government research at all,
the true prevalence could be one-third to two-thirds
higher than the NHANES estimate. In addition,
NHANES phlebotomists reported that at times they
were unable to obtain a blood sample because prior
illicit injection drug use made venipuncture too diffi-
cult.4 A study of nonresponse bias in a household survey
of human immunodeficiency virus (HIV) seroprevalence
illustrates the potential magnitude of this effect. Persons
who declined to participate in the seroprevalence survey
(but consented to be interviewed in a subsequent study)
were more than twice as likely as survey responders to
report a history of injection drug use.76 (Of note, adjust-
ment for nonresponse of this magnitude still resulted in
an underestimate of the HIV seroprevalence compared
with estimates determined by other methods; back-
calculation models yielded estimates 1.8-fold to 4.6-fold
higher than the estimate derived from the household
survey even after nonresponse bias was accounted for).76
Fourth, while NHANES oversamples African Ameri-
cans and Mexican Americans to improve representation of
Table 6. New Estimate of Number of Individuals in the United States With Hepatitis C Antibody
Estimate
HCV Antibody-Positive
Number (Range)
HCV RNA-Positive
Number (Range)
NHANES (2003-2010) 3.6 million (3.0 million-4.2 million) 2.7 million (2.2 million-3.2 million)
Added populations 1.0 million (0.4 million-1.8 million) 0.8 million (0.3 million-1.5 million)
Total 4.6 million (3.4 million-6.0 million) 3.5 million (2.5 million-4.7 million)
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these populations, it is unable to adequately sample other
groups who may have elevated hepatitis C prevalence,
including other ethnic minority groups and people born
in high-prevalence countries.5-9 Thus, although these
groups are not excluded from the NHANES sampling
frame, they are nonetheless poorly represented in the sur-
vey.6 Hepatitis C prevalence is elevated among Puerto
Rican Americans5 and immigrants from Egypt7 and
Somalia,8 for example; and in one study of immigrants
from the former Soviet Union, of whom some 2.9 million
are living in the United States, the HCV seroprevalence
was 28.3%.9 The seroprevalence among immigrants from
other high-prevalence countries77 is unknown.
Fifth, all household surveys miss people, even among
groups that are not poorly represented or excluded from
the sampling frame. Studies of the 2000 US census cov-
erage, for example, estimated that 3 million to 4 mil-
lion people were uncounted.78,79 Uncounted persons
are disproportionately young, single, male, poor, of
minority ethnicity, and therefore on average more likely
to have hepatitis C. The coverage of national household
surveys such as NHANES, with only a fraction of the
resources available to the US census to reach disadvan-
taged groups, is likely to be at least as impaired in this
regard.
Finally, NHANES has limited ability to discern new
transmission patterns concentrated in specific foci in
population subgroups. Increased HCV transmission is
occurring in at least 30 states, especially in rural and
suburban areas, on the heels of dramatic increases in
opioid use among young adults during the past dec-
ade.80-83 These new infections have yet to register in
NHANES.
For these reasons, the findings presented here may
still underestimate the true number of HCV-infected
persons in the United States. The present study exam-
ined only one of several sources of potential underesti-
mation. Further work is needed to assess the
contributions of these other possible sources of error
in the estimate, as has been done for HIV.84 An analysis
of the NHANES HIV prevalence estimate concluded
that the true HIV seroprevalence was 1.4-fold to 2.0-
fold higher than the NHANES estimate because of
nonresponse bias and the exclusion of high-risk popula-
tions.4,85 If HCV seroprevalence was underestimated by
a similar proportion—and there is little reason to think
it was not—the true seroprevalence of HCV would be 5
million to 7 million.
This study illustrates the limitations of household sur-
veys for ascertaining sequelae of stigmatized behavior.
Injection drug use is highly prevalent in prisons and
marginally housed populations because our nation
criminalizes and incarcerates people who inject drugs
and disqualifies them from receiving public aid such as
housing assistance. And because we stigmatize illicit
drug use, those who have used drugs and are free and
housed are understandably reluctant to disclose it. Thus,
the National Household Survey on Drug Abuse esti-
mated that 440,000 persons in the United States had
injected illicit drugs in the past year, while contempora-
neous estimates from other sources put the figure at 1.5
million to 2.0 million.86,87 Over 1 million people who
injected drugs were either missed or misclassified in that
household survey. Because 50%-90% of people who
currently inject illicit drugs have HCV antibody
(depending on the duration of their use),88,89 this pro-
vides further support for the likelihood that among cur-
rent injectors alone, a million more Americans have
been infected with HCV than might be detected by a
household survey.
These limitations underscore the need for better
assessment and monitoring of the health needs of
socially marginalized populations. This problem impairs
public health responses to nearly all diseases, not just
hepatitis C: surveillance systems are not accurate if they
overlook disenfranchised groups.6 Hepatitis C preva-
lence estimates should not be based on NHANES alone
but should be augmented with expanded HCV screen-
ing, case surveillance, and focused seroprevalence studies
of established and emerging groups at elevated risk.
These testing initiatives can provide data for surveillance
purposes at the same time as they identify infected per-
sons and link them to care and treatment.
For the meantime, projections based on NHANES
data may underestimate current health disparities and
the burden of liver disease that can be expected in the
coming decades. Most models projecting the future
disease burden use NHANES estimates without correc-
tion for the excluded populations or other sources of
underestimation.90-93 As new highly effective antiviral
regimens offer the hope of transforming the hepatitis C
epidemic, it will be important to plan appropriately.89,94
These findings may heighten concern about the
affordability of providing antiviral treatment to all who
need it. Only an estimated 5%-6% of infected people in
the United States have been successfully treated.11 It is
important to realize, however, that curative antiviral
treatment, and the associated costs, will occur over
many years. Most people with hepatitis C do not yet
know their status,11,95 and many of the groups discussed
in this article have substantial barriers to health care
access.94 Resources for addressing these deficiencies have
not kept pace with the need.89 It will take years of con-
certed effort before most infected people, especially
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those in underserved groups, are tested, engaged in care,
and referred for treatment. Indeed, a national commit-
ment will be needed to bring screening, treatment, and
prevention services to these populations.11,89,94,95
Currently, however, public and private payers are lim-
iting access to the new, high-priced oral drugs for hepa-
titis C, requiring abstinence from drugs and alcohol and
the presence of advanced liver disease,96,97 which means
that HCV will continue to spread among the highly
affected groups most in need, such as young people who
inject drugs.80,81 More accurate estimates of hepatitis C
prevalence and incidence can help inform the planning
and negotiation of strategies to reach, test, treat, cure,
and prevent every case of hepatitis C.94
Appendix A: Sex Ratio Methods
Where sex-specific prevalence rates were available, we
calculated the M:F ratio of infected persons by multiply-
ing the M:F prevalence in each study with sex-specific
prevalence data20,28,32-36,38,41-45,49,52,53,64,65 by the sex ratio
of the population:
M:F ratio of infected persons5M:F prevalence ratio 3
M:F sex ratio of population
This is true because:
No: infected women in population
No: infected men in population
¼
HCV prevalence in women
HCV prevalence in men
3
Total no: women in population
Total no: men in population
For prison studies we used the sex ratio of the respective
state prison system. For homeless studies we used the
estimated overall national sex ratio.
We then converted the M:F ratio of infected persons to the
percentage of men over the percentage of women. For prison
and homeless studies we averaged the percentages, weighting
prison studies by the total prison population for the respective
state and homeless studies by the sample size of the study. For
the military population, we used the one representative
national study64 (self-weighted with respect to sex ratios) and
calculated the M:F ratio of infected persons directly.
Appendix B: Projected Seroprevalence of
People Living in Prison Versus People
Entering Prison
Background. Entrants to prison are younger than
the overall prison population. This is true not only
because persons age while they serve time in prison but
also because prison populations are enriched with people
serving longer terms, in proportion to the length of time
they serve. The mean age of people entering prison in the
United States in 2012 was 33 years, while the mean age of
people living in prison was 36 years.98 Thus, because
HCV prevalence is strongly associated with older age in
people <65 years (the age of 98% of prisoners), the HCV
prevalence of prison entrants underrepresents the HCV
prevalence of people serving time in prison.
Methods and Results. To determine the effect on
HCV seroprevalence of the age difference between people
entering prison and people living in prison, we used pub-
lished data on HCV prevalence rates by birth cohort of
entrants to prison in Pennsylvania.41 The age distribution
of entrants to prison in Pennsylvania was similar to that
of entrants to prison nationwide.98 While the HCV preva-
lence of persons entering prison in Pennsylvania might
not represent the prevalence of persons entering prison
nationwide, we used the distribution of rates by birth
cohort as a proxy for the distribution by birth cohort
nationwide. (For example, the peak prevalences in Penn-
sylvania entrants were in the 1945-1965 birth cohort, sim-
ilar to the national household survey data).10 When we
applied the birth cohort–specific prevalence data from
Pennsylvania to the age distribution of entrants in 2012
nationwide, we obtained an overall HCV prevalence simi-
lar to that reported from Pennsylvania (17.9% versus
18.1%). When we then applied the same prevalence data
to the age distribution of persons serving time in prison
in 2012 nationwide, the calculated prevalence was 20.3%.
The difference in projected HCV prevalence between the
entrants (17.85%) and persons serving time (20.30%) was
2.45%.
Summary. To adjust the projected seroprevalence of
prisoners for the difference between the age of people
entering prison and the age of people living in prison, we
applied the birth cohort–specific HCV prevalences of
persons entering prison in Pennsylvania41 to the age dis-
tributions of persons entering prison and persons living
in prison nationwide. The projected prevalence of persons
serving time was 2.45% greater than the projected preva-
lence among entrants.
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